Spasmine (Alverine) is commonly used for managing symptoms related to heightened physiological activity and tension within internal smooth muscles. Its therapeutic application generally offers supportive benefit and is relevant in contexts involving heightened systemic burden and muscle spasm.

---

This medication is applied in conditions marked by increased discomfort or tension, relevant for easing symptoms associated with functional bowel disorders, painful diverticular disease of the colon, and primary dysmenorrhoea (menstrual cramping). It helps address symptom clusters that may become intense or disruptive, particularly abdominal pain, cramping, and bloating. The medication is applied in clinical settings that involve acute or unstable symptom patterns, such as recurrent or episodic manifestations of Irritable Bowel Syndrome (IBS). It provides support that helps ease the overall symptom burden, and helps maintain a sense of stability when symptoms interfere with routine activities. For women, it is used for managing pronounced uterine muscle spasms related to the menstrual cycle.

Quick Fact: Support for Visceral Discomfort
Used for: Symptoms related to physical discomfort.
Benefit: Supports easing the overall symptom load.
Context: Used during phases of increased distress.

Regulatory References

1. Health Products Regulatory Authority (HPRA) SmPC

Who Can and Cannot Use Spasmine?

The population eligibility for Spasmine (Alverine) is strictly defined by government regulatory documents, which establish clear criteria for approved use, conditional use, and absolute prohibition.

Contraindications and Prohibited Use

Use is contraindicated for individuals with known hypersensitivity to Alverine citrate or any of its non-active components. Furthermore, the medicine must not be used in the presence of two serious conditions affecting gut motility: Intestinal Obstruction or Paralytic Ileus.

Age and Reproductive Status

• Pediatric Use: The medicine is contraindicated and not recommended for children under 12 years of age. Use is approved for adults and children aged 12 years and above.
• Reproductive Status: Use is contraindicated during both pregnancy and lactation. This restriction is due to insufficient safety data or the unknown excretion of the substance into human milk.

Conditional Eligibility

Specific clinical findings require a medical consultation before use. These conditional restrictions apply to patients presenting with certain "red flag" symptoms (e.g., unexplained weight loss, vomiting, or passing blood from the bowel) or those experiencing severe constipation.

The official interaction profile for Alverine (Spasmine) is defined by its primary pharmacodynamic effect and a logistical constraint related to administration timing, as outlined in government regulatory documentation.

Documented Interaction Classifications

Category	Regulatory Basis
Pharmacodynamic Additive Effects	Co-administration with alcohol or other CNS depressant drugs may increase the risk or severity of central nervous system effects, such as drowsiness.
Absorption Interference Risk	The spasmolytic activity may potentially alter the absorption of certain co-administered oral medications.

---

Administration Timing Constraints

The most specific interaction rule documented in regulatory sources concerns the simultaneous use of Alverine with absorption-sensitive oral medications. For such co-administered products, the regulatory condition recommends that the respective doses should be separated by four hours if possible to mitigate the potential for absorption interference.

Official prescribing information generally notes that no specific drug-drug interactions are known or reported that involve major Cytochrome P450 (CYP) enzymes or specific drug transporters. The overall interaction structure, therefore, focuses strictly on managing additive sedative effects and ensuring proper absorption of other orally administered products.

How Spasmine Works

Spasmine is a multi-component agent that primarily acts by engaging mechanisms that regulate overactive or dysregulated physiological processes within the nervous system and circulatory pathways. The drug's action can be segmented into two main mechanistic domains:

---

Modulation of Key Neurotransmitter Pathways

This domain involves compounds that affect systems where specific neurotransmitters or mediators dominate, specifically targeting the central nervous system. The drug initiates sequences that enhance the activity of inhibitory mediators, such as GABA, which are key to regulating excitability. This results in a modification of early molecular steps in neuronal signaling that contributes to reduced physiological excitability.

---

Engagement of Cardiac and Vascular Regulation Mechanisms

The drug acts within domains involving key cardiac-related pathways to influence the maintenance of systemic pathway activity within the circulatory system. It modulates pathways associated with heightened physiological responses by influencing factors that regulate heart rhythm and vessel tone. This engagement leads to predictable physiological adjustments and influences the degree of signal transmission mediated by high levels of signaling molecules within the cardiac and vascular systems.

How to Use Spasmine

Spasmine, which contains the active ingredient Alverine Citrate, is administered through the oral route as a hard capsule formulation. The usage of this medication follows established guidelines which define the dosing schedule and administration method.

Official Administration Guidelines

Feature	Guideline
Route of administration	Oral administration is the only approved route for this form.
Dosing schedule (Adults)	The standard single dose is 60 mg or 120 mg of Alverine Citrate.
Frequency pattern	The dose is typically taken up to three times per day (i.e., divided daily dosing).
Timing in relation to meals	The capsule may be taken with or without food.
Preparation requirements	Capsules must be swallowed whole with water; they should not be crushed or chewed.
Age-group exclusion	Use is not recommended for children below the age of 12 years.

---

Procedural Context and Constraints

The usage protocol establishes clear conditions for administration. If a dose is forgotten, the instruction is to skip the missed dose and not take a double dose to compensate, maintaining the scheduled dosing pattern. The patient should consult a doctor if their condition does not improve after a period of approximately two weeks of use, which sets a preliminary duration for treatment assessment. This information describes the standardized administration profile.

Evidence for Use in Functional Gastrointestinal Spasm

Research examined the patterns of response in individuals with physical discomfort associated with conditions such as Irritable Bowel Syndrome (IBS). These studies included controlled clinical trials that compared the medicine against a placebo. Researchers primarily monitored short-term symptom patterns in adult populations, exploring patient-reported outcomes for abdominal pain, cramping, and overall global symptoms. Findings were mixed across studies that focused on the single active ingredient. The high placebo response pattern in these conditions makes interpreting observed patterns challenging, and sustained patterns of response remain an area where evidence is limited.

Evidence for Use in Primary Dysmenorrhoea

Research evaluated the use of the medicine in settings relevant to primary dysmenorrhoea, a condition involving temporary physiological imbalance in the uterine muscles. Studies described outcomes related to physical discomfort, such as the severity and duration of menstrual cramping during cycles. Evidence quality varies across studies for this specific use, and comparative evidence is lacking against other agents that were observed in similar research scenarios.

Long-Term Studies and Follow-Up Periods

Clinical trials generally focused on defined time intervals of a few weeks up to a few months. Because these follow-up durations were limited, long-term effects are not fully established. Limited information exists for outcomes sustained over many months or years, and data suggest patterns related to short-term changes only.

Research in Special Populations and Uncertainties

The research has primarily focused on general adult populations. Data for certain groups, such as older adults or patients with specific co-existing chronic conditions, remain insufficient. The level of certainty remains low for some outcomes due to the high placebo effect and mixed findings across trials. Research highlights what is known—and what is still uncertain—emphasizing that more research is needed to fully characterize all outcomes in the long term and across all patient subgroups.

Key Studies & References Spasmonal (Alverine Citrate) - Summary of Product Characteristics (SmPC) (Health Products Regulatory Authority - HPRA)

Common questions about Spasmine (FAQ)

---

Q: Is Spasmine considered an opioid or a controlled substance?

A: Official classifications place Spasmine (Alverine) as a musculotropic antispasmodic, which means it acts directly on smooth muscles. It is chemically defined as a specific type of compound. Regulatory documents do not classify the medicine as an opioid or a scheduled controlled substance under standard drug regulatory systems.

Q: Does Spasmine interact with common over-the-counter pain relievers like ibuprofen?

A: Official prescribing information states that no specific drug-drug interactions are known or reported with other medicinal products. The main precaution noted in the labeling is that separating the dosing of absorption-sensitive oral medications, if possible, by four hours may help mitigate potential absorption interference.

Q: Can Spasmine affect the results of laboratory tests, like blood work?

A: According to the official product information, abnormal liver function test results are listed as a possible undesirable effect (side effect). The regulatory description notes that this is often an effect that resolves upon cessation of the medicine.

Q: Is it necessary to finish a specific course of Spasmine, or can I stop when symptoms improve?

A: Official instructions advise consulting a doctor if symptoms worsen or do not improve after a specific period of treatment, typically around two weeks. The regulatory information does not provide non-directive, non-clinical guidance on stopping treatment upon symptom improvement.

Q: Is Spasmine safe to use if I am also taking medication for depression or anxiety?

A: The regulatory information warns that co-administration with other CNS depressant drugs may increase the risk of central nervous system effects, such as drowsiness or sedation.

Q: Does Spasmine interact with contraceptives (birth control pills)?

A: Official documents caution that the drug's activity may potentially alter the absorption of certain co-administered oral medications. For absorption-sensitive products, including some oral contraceptives, it is suggested that the doses be separated by four hours, if possible, to minimize interference risk.

Q: What is the main difference between Spasmine and other anti-spasmodic drugs?

A: Official documents classify Spasmine (Alverine) as a musculotropic antispasmodic. This means its action is primarily direct on the smooth muscle tissue of the gastrointestinal and uterine tracts. Its specific action on smooth muscle is what distinguishes it from agents that primarily act on skeletal muscles.

Q: How quickly does Spasmine usually start working?

A: Based on pharmacokinetic data from official sources, the drug's active metabolite reaches its peak plasma level between one and one and a half hours after taking the oral dose. This peak level corresponds to the period of highest concentration in the bloodstream.

Q: What is the typical duration of Spasmine's effect after one dose?

A: Pharmacokinetic studies show that the average plasma half-life for the primary active metabolite is approximately 5.7 hours. The half-life is the time it takes for the concentration of the medicine in the body to be reduced by half.

Q: Is it common to feel drowsy after taking Spasmine?

A: Official regulatory documents list dizziness and headache as possible undesirable effects, but their frequency is classified as "Not known". This classification means the rate of occurrence cannot be reliably estimated from the available data.

Q: Are there any foods or drinks I should avoid while taking Spasmine?

A: Official documents specifically warn that co-administration with alcohol may increase the risk of central nervous system effects, such as drowsiness. Beyond this warning, the medicine may be taken with or without food.

Q: Does Spasmine have a potential for misuse or dependence?

A: Official regulatory documents describe the drug's mechanism as a direct-acting spasmolytic. They do not mention specific warnings or precautions regarding potential for abuse, misuse, or dependence.

Q: Does taking Spasmine affect my ability to drive or operate machinery?

A: Official documents advise that Spasmine may cause dizziness. If affected by dizziness or similar central nervous system effects, it is recommended to avoid activities that require alertness, such as driving or operating machinery.

Q: Has Spasmine been studied in pediatric populations?

A: Official documents state that the use of Spasmine is not recommended for children below the age of 12 years. This restriction indicates that sufficient or appropriate safety and efficacy data for younger pediatric populations are limited or absent.

Q: What is the risk of an allergic reaction to Spasmine?

A: Serious adverse reactions, including allergic reaction and anaphylaxis (a severe systemic allergic reaction), are documented in official labeling. However, the frequency of these events is categorized as "Not known," meaning the rate of occurrence cannot be reliably estimated from available data.

Q: Is it normal to have a slight headache when first starting Spasmine?

A: Headache is listed as a possible undesirable effect in the official product information. Its frequency is classified as "Not known" in regulatory documents, and the information does not provide data specifically on its occurrence when first starting the medicine.

Q: How does Spasmine work differently from a skeletal muscle relaxant?

A: Official documents describe Spasmine as a musculotropic antispasmodic that acts specifically on the smooth muscle of the alimentary tract and uterus. It is noted that the medicine does not affect the skeletal muscle at therapeutic doses, which is the key difference from skeletal muscle relaxants.

Q: What is the difference between the 'on-label' use and how Spasmine is sometimes discussed online?

A: The approved uses (on-label indications) are strictly defined in official documents and are limited to the relief of smooth muscle spasm in conditions such as Irritable Bowel Syndrome, painful diverticular disease, and primary dysmenorrhoea. Any other use is outside of the official defined labeling.

Q: Is there a version of Spasmine that is chewable or liquid?

A: The official regulatory documents specify the product form as a hard capsule intended for oral use, which must be swallowed whole. Other formulations, such as chewable or liquid versions, are not typically noted in the official labeling.

Q: What if I take Spasmine and it doesn't seem to be working?

A: Official instructions advise that if symptoms worsen or if they do not improve after a period of approximately two weeks of treatment, consultation with a doctor is necessary for further assessment.

Q: Is Spasmine recommended for people who have frequent migraines?

A: The officially approved uses are limited to relief of smooth muscle spasm in conditions such as Irritable Bowel Syndrome, painful diverticular disease, and primary dysmenorrhoea. Migraines are not listed as an approved indication in the official labeling.

Q: Are there any specific studies about Spasmine's use in women?

A: Yes, one of the official indications for use is primary dysmenorrhoea (period pain). This is a condition specific to women, indicating that the drug has been assessed and approved for use in that context.

Q: Is the onset of action different depending on the dosage form of Spasmine?

A: The regulatory documents describe the pharmacokinetics, including the peak plasma level, for the oral capsule formulation specifically. No specific comparative pharmacokinetic data for different dosage forms (if any exist) are typically included in the official labeling.

Storage and Disposal Requirements for Spasmine

All storage and disposal rules for Spasmine (alverine citrate) are defined by official regulatory labeling to ensure product stability and safety.

Storage and Child Safety

Spasmine must be kept out of the sight and reach of children.

The medicine should be stored under temperature-controlled conditions, typically requiring storage below 25°C or not above 30°C in certain formulations. To maintain product integrity, the capsules must be kept in the original packaging and not used after the expiry date printed on the label.

Disposal Instructions

For public health and environmental protection, unused or expired Spasmine should not be thrown away via wastewater or household waste. Any unused product or waste material must be disposed of in accordance with local requirements. Official guidance recommends asking your pharmacist for instructions on safe disposal.